|Calculated MW||98314 Da|
|Other Names||Proto-oncogene vav, VAV1, VAV|
|Target/Specificity||A synthetic peptide corresponding to residues near the C-terminus of human Vav was used as an immunogen.|
|Format||50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||Vav Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Couples tyrosine kinase signals with the activation of the Rho/Rac GTPases, thus leading to cell differentiation and/or proliferation.|
|Tissue Location||Widely expressed in hematopoietic cells but not in other cell types|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The Vav family are Rho/Rac guanosine nucleotide exchange factors (GEFs), consisting of three members in mammalian cells (Vav, Vav2, Vav3) and one in nematodes (CelVav) (1). First discovered based on its transforming properties, Vav is expressed mainly in hematopoietic cells and a few non-hematopoietic tissues, such as the pancreas and tooth enamels (2). As a signaling transducer, Vav is involved in T-cell activated transduction of T-cell antigen receptor (TCR). T-cell stimulated and tyrosine phosphorylated Vav acts as a catalyst in the exchange of guanosine nucleotides on Rac-1, a GTP binding protein (3). Using a mouse model, Vav expression has been determined to play an essential role in the cytoskeletal, proliferative, and apoptotic pathways for developing lymphoid cells and its signal response (2).
1. Bustelo XR. Rev Oncog 7:65-88, 1996.
2. Bustelo XR. Mol Cell Biol 20:1461-1477, 2000.
3. Turner M, et al. Immunity 7:451-460, 1997.
If you have any additional inquiries please email technical services at email@example.com.